An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma

The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of st...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of translational medicine 2016-05, Vol.14 (1), p.142-142, Article 142
Main Authors:	Formicola, Daniela, Petrosino, Giuseppe, Lasorsa, Vito Alessandro, Pignataro, Piero, Cimmino, Flora, Vetrella, Simona, Longo, Luca, Tonini, Gian Paolo, Oberthuer, André, Iolascon, Achille, Fischer, Matthias, Capasso, Mario
Format:	Article
Language:	eng
Subjects:	Care and treatment Child, Preschool Development and progression Female Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Gene Ontology Gene Regulatory Networks Genetic aspects Humans Kaplan-Meier Estimate Male Multivariate Analysis Neuroblastoma Neuroblastoma - genetics Patient outcomes Physiological aspects Prognosis Proportional Hazards Models Regression Analysis Reproducibility of Results Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The prognosis of children with metastatic stage 4 neuroblastoma (NB) has remained poor in the past decade. Using microarray analyses of 342 primary tumors, we here developed and validated an easy to use gene expression-based risk score including 18 genes, which can robustly predict the outcome of stage 4 patients. This classifier was a significant predictor of overall survival in two independent validation cohorts [cohort 1 (n = 214): P = 6.3 × 10(-5); cohort 2 (n = 27): P = 3.1 × 10(-2)]. The prognostic value of the risk score was validated by multivariate analysis including the established markers age and MYCN status (P = 0.027). In the pooled validation cohorts (n = 241), integration of the risk score with the age and/or MYCN status identified subgroups with significantly differing overall survival (ranging from 35 to 100 %). Together, the 18-gene risk score classifier can identify patients with stage 4 NB with favorable outcome and may therefore improve risk assessment and treatment stratification of NB patients with disseminated disease.
ISSN:	1479-5876 1479-5876